Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naizilai granules are an investigational **Uyghur multi-herb medicine** for common cold, specifically the heat-type common-cold syndrome. The granule formulation is derived from a longstanding clinical formula and contains eight herbal materials: Artemisia rupestris, hyssop, Tianshan violet, lettuce seed, Cordia fruit, chamomile, jujube, and mint. It has completed a Phase II study and has been evaluated in a multicenter randomized, double-blind, placebo-controlled Phase III trial for common cold. Its pharmacology is not defined by a single drug target; preclinical work has reported anti-inflammatory and analgesic activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Naizilai granules.